scar tissue

Compounds designed to alter genetic instructions for dystrophin, increase production of utrophin, or prevent scar tissue formation in muscle are moving through the development pipeline

posted on November 5, 2014 - 4:03pm
Drug development for Duchenne muscular dystrophy (DMD) is progressing on several fronts. Here are some updates as of early November 2014. PTC is moving forward with ataluren

An MDA Venture Philanthropy grant of $500,000 to Halo Therapeutics will support the development of HT-100, an experimental drug for Duchenne muscular dystrophy

posted on November 14, 2013 - 7:00am
Update (June 12, 2014):  In a June 12, 2014, announcement, Halo Therapeutics said that it has resumed testing of HT-100, an experimental oral drug intended to reduce scar formation and inflammation and promote healthy muscle regeneration in DMD. The company will now continue to enroll and dose DMD ptients in its ongoing clinical trial and extension study.